ReviewMycology2024
Risk of candidiasis associated with interleukin-17 inhibitors: Implications and management.
Review in Mycology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Immunotherapy in Ocular Fungal Infections: Advances and Emerging Strategies.Current microbiology · 2026Review
- Antimicrobial activity of a decapeptide againstMicrobiology spectrum · 2026Article
- Biologic and targeted synthetic therapies in ankylosing spondylitis: a pharmacological review.Frontiers in pharmacology · 2026Review
- The trio of Candida albicans, immune cells, and cancer progression: a complex interplay driving tumorigenesis.Medical oncology (Northwood, London, England) · 2025Review
- Article
- Anti-Inflammatory Potential of Extracellular Polysaccharide from the Moss EndophyteMicroorganisms · 2025Article
- Friend or foe? Sebaceous cyst inflammation during ixekizumab therapy in psoriatic arthritis: case based review.Rheumatology international · 2025Review
- Recurrent Vulvovaginal Candidosis and Its Underlying Mechanisms: A Systematic Review.Journal of fungi (Basel, Switzerland) · 2025Review
- Genetic susceptibility to recurrent vulvovaginal candidiasis in an African population from Nairobi, Kenya.Scientific reports · 2025Article
- Biologics and small molecules for psoriasis: current and future progress.Drugs in context · 2025Review
- Bimekizumab for Hidradenitis Suppurativa from Trials to Real Life: A Review of the Published Literature.Clinical, cosmetic and investigational dermatology · 2025Review
- Host-microbe interaction paradigms in acute and recurrent vulvovaginal candidiasis.Cell host & microbe · 2024Review
- The Impact of Oral Microbiome Dysbiosis on the Aetiology, Pathogenesis, and Development of Oral Cancer.Cancers · 2024Review
- Interleukin inhibitors and the associated risk of candidiasis.Frontiers in immunology · 2024Review
- Deciphering the role of IL17RA in psoriasis and chronic mucocutaneous candidiasis: shared pathways and distinct manifestations.Frontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 12 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The application of interleukin-17 (IL-17) inhibitors, including secukinumab, ixekizumab, brodalumab, and bimekizumab, are associated with elevated risk of candidiasis. These medications interfere with the IL-17 pathway, which is essential for maintaining mucosal barriers and coordinating the immune response against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.